Great Point Partners’s Rein Therapeutics RNTX Stock Holding History
Bought
Maintained
Sold
Other funds holding RNTX
Great Point Partners's RNTX Position: Q3 2026 in Review
Great Point Partners reduced its Rein Therapeutics (RNTX) stake by 35% in Q3 2026, selling an estimated $748K and leaving 1,663,144 shares worth $1.34M. The position accounts for 0.32% of the portfolio, ranked #43.
Great Point Partners first reported a position in RNTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $2.68M in Q2 2026. 63 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.
- Great Point Partners held 1,663,144 shares of Rein Therapeutics worth $1.34M as of Q3 2026.
- Great Point Partners sold 911,856 Rein Therapeutics shares in Q3 2026, an estimated $748K.
- Rein Therapeutics made up 0.32% of Great Point Partners's portfolio in Q3 2026, its #43 holding.
- Great Point Partners first reported a position in Rein Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Great Point Partners's Rein Therapeutics position peaked at $2.68M in Q2 2026.
- 63 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.
Based on Great Point Partners's 13F filing for Q3 2026, filed 16 Nov 2026.